Immunosuppression Related to Collagen-Vascular Disease or Its Treatment
- 1 December 2005
- journal article
- review article
- Published by American Thoracic Society in Proceedings of the American Thoracic Society
- Vol. 2 (5), 456-460
- https://doi.org/10.1513/pats.200508-091js
Abstract
Collagen-vascular diseases are associated with immune dysregulation and inflammation, leading to tissue destruction or compromise. Immunosuppression is more commonly associated with the drugs used to treat these disorders than with the diseases themselves. The newest agents being used to treat collagen-vascular diseases are the tumor necrosis factor (TNF)-α inhibitors. U.S. Food and Drug Administration–approved TNF-α inhibitors have differing effects on the immune system, reflecting their potency and mechanisms of action. They are particularly effective in breaking down granulomatous inflammation, which makes them effective treatment for sarcoidosis and Wegener's granulomatosis. This same property makes them likely to break down the host defense mechanism that normally contains pathogens such as mycobacteria and fungi in a dormant state, namely the physical and immunologic barrier formed by granulomas in the lung and elsewhere. The most common infection reported with the TNF-α inhibitors has been tuberculosis, which may manifest as pulmonary and/or extrapulmonary disease, with the latter being more common and severe than usual. Histoplasma capsulatum, Aspergillus, Cryptococcus neoformans, and Listeria monocytogenes have also been described in a number of cases, and their frequency is discussed.Keywords
This publication has 34 references indexed in Scilit:
- Treatment of tuberculosis.2003
- Histoplasmosis after Treatment with Anti–Tumor Necrosis Factor-α TherapyAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agentsArthritis & Rheumatism, 2003
- Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agentsAnnals Of The Rheumatic Diseases, 2002
- Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanerceptArthritis & Rheumatism, 2002
- Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor AntagonistsThe Journal of pharmacology and experimental therapeutics, 2002
- Tumor necrosis factor-α antagonists for the treatment of rheumatic diseasesCurrent Opinion in Rheumatology, 2002
- Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting PathologyInfection and Immunity, 2001
- Factors involved in regulating primary and secondary immunity to infection with Histoplasma capsulatum: TNF-alpha plays a critical role in maintaining secondary immunity in the absence of IFN-gamma.1998
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995